Researchers used a genetically modified herpes virus to treat advanced melanoma in a recent phase 2 clinical trial. Design by MNT; Photography by Smith Collection/Gado/Getty Images Advanced melanoma patients often face a risk of recurrence postsurgery. New approaches, like immunotherapies before surgery, could potentially help improve the body’s ability to fight cancer and improve patient...
A genetically modified version of the herpes virus has shown great potential in treating advanced cancers, according to a report by the Institute of Cancer Research in London published on Thursday. A promising therapy Although the treatment is still in early trials, researchers have found that RP2, a modified version of the herpes simplex virus,...
by Institute of Cancer Research Carcinoma of salivary gland. Credit: Nephron, CC BY-SA 4.0, via Wikimedia Commons A new genetically engineered virus has delivered a one-two punch against advanced cancers in initial findings from a phase I trial. Researchers found that RP2—a modified version of the herpes simplex virus—showed signs of effectiveness in a quarter...
Emily Waltz Particles of the SARS-CoV-2 virus (blue) inside an infected cell.Credit: NIH/SPL Researchers looking for biological drivers and markers of long COVID have linked the syndrome to herpes viruses, as well as to reduced levels of a stress hormone1. The exploratory study drew both praise and criticism from scientists contacted by Nature. “A major weakness...
by Fraunhofer-Gesellschaft For experimental purposes, the programmable herpes simplex virus is propagated in cell cultures in an incubator. Credit: Fraunhofer-Gesellschaft Viruses are simple in structure: They consist of a small amount of genetic material wrapped in proteins and lipids. Measuring just 20 to 200 nanometers in size, they can only be detected with an electron...
by University of Nebraska-Lincoln A genetically edited form of a herpes simplex virus has outperformed a leading vaccine candidate in a study published Nov. 6. Nebraska researchers Patricia Sollars (left) and Gary Pickard teamed with colleagues from the University of Cincinnati and Northwestern University to develop and test a form of HSV that generates high levels...
